Mumbai, May 13, 2025: Remedium Lifecare Ltd. is focusing on bolstering its Contract Development and Manufacturing Organization (CDMO) services and research & development (R&D) capabilities. This initiative is part of the company’s broader plan to strengthen its global presence, particularly in the UK and Europe.
On the 8th day of the rights issue, the company received a nearl 50% subscription of the total issue size, amounting to ₹ 24.28 crores. Bids received totalled ₹ 24,27,93,851 for shares priced at ₹1 each.
CDMO set up will mark Remedium’s transition from a trader to an integrated pharmaceutical solutions provider. While no additional manufacturing capacity is being added, this CDMO upgrade will establish a dedicated quality control and testing infrastructure, enabling the facility to serve as a hub for testing incoming raw materials and finished products.
Mr. Adarsh Munjal, Whole Time Director of Remedium Lifecare Ltd stated: “Our focus is to build a robust foundation for CDMO and R&D services that will position Remedium to secure new contracts, drive innovation, and improve margins through backward integration. The upgraded facility will not only support testing activities but also accelerate the development of new products and intermediates for international markets.
Key features of the upgrade include:
Installation of advanced testing equipment for inward and outward material validation Expansion of laboratory space to support R&D activities and product development pipelines
Dedicated infrastructure to facilitate CDMO-related projects for international clients Unlike regulated market facilities, the selected CDMO site is not associated with compliance requirements from regulatory bodies such as the USFDA or EU. The upgrades are therefore tailored to meet customer-specific quality standards while enabling greater flexibility in project execution.
The facility’s enhanced capabilities are expected to improve operational efficiency and unlock new opportunities in global markets, particularly in the UK and Europe, where Remedium recently secured a ₹182.7 crore multi-year export contract with a leadingpharmaceutical distributor.Adarsh Munjal added: “This investment aligns with our long-term strategy of buildingvalue-accretive assets that drive sustainable growth. By strengthening our CDMO and R&D ecosystem, we aim to deepen client relationships, expand our global footprint, andcreate a platform for future product innovation.”Remlife Global PTE Ltd., a Singapore-based subsidiary of Remedium Lifecare, had partnered with green chemistry technology platform JiyaYu Lifesciences to replace animal-origin raw materials in Active Pharmaceutical Ingredient (API) manufacturing.
JiyaYu will license fully developed technologies to Remlife Global, which will replacetraditional animal-derived steps with sustainable, cost-effective, and regulatory compliant bioprocesses. Remlife Global will scale up and commercialize these technologies at GMP-compliant contract manufacturing sitesThe rights issue provides the financial impetus for this phase of development, with the renunciation window running from April 30 to May 9, 2025, and the issue closing on May 14, 2025. By backing the issue, investors are contributing to a critical milestone in Remedium’s journey toward becoming a diversified pharmaceutical solutions partner in the global healthcare ecosystem.